Your browser doesn't support javascript.
loading
Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis.
Kehr, Sarah; Berg, Philipp; Müller, Susanne; Fiedler, Sarah A; Meyer, Britta; Ruppert-Seipp, Gabriele; Witzenhausen, Cornelia; Wolf, Marc E; Henkes, Hans H; Oberle, Doris; Keller-Stanislawski, Brigitte; Funk, Markus B.
Afiliação
  • Kehr S; Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedicines), Division Safety of Medicinal Products and Medical Devices, Langen, Germany.
  • Berg P; Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedicines), Division Safety of Medicinal Products and Medical Devices, Langen, Germany.
  • Müller S; Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedicines), Division Safety of Medicinal Products and Medical Devices, Langen, Germany.
  • Fiedler SA; Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedicines), Division Safety of Medicinal Products and Medical Devices, Langen, Germany.
  • Meyer B; Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedicines), Division Safety of Medicinal Products and Medical Devices, Langen, Germany.
  • Ruppert-Seipp G; Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedicines), Division Safety of Medicinal Products and Medical Devices, Langen, Germany.
  • Witzenhausen C; Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedicines), Division Safety of Medicinal Products and Medical Devices, Langen, Germany.
  • Wolf ME; Department of Neurology, Klinikum Stuttgart, Stuttgart, Germany.
  • Henkes HH; Department of Neuroradiology Klinikum Stuttgart, Stuttgart, Germany.
  • Oberle D; Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedicines), Division Safety of Medicinal Products and Medical Devices, Langen, Germany.
  • Keller-Stanislawski B; Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedicines), Division Safety of Medicinal Products and Medical Devices, Langen, Germany.
  • Funk MB; Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedicines), Division Safety of Medicinal Products and Medical Devices, Langen, Germany. markus.funk@pei.de.
NPJ Vaccines ; 7(1): 76, 2022 Jul 05.
Article em En | MEDLINE | ID: mdl-35790739
ABSTRACT
We present the long-term outcomes of 44 patients who developed cerebral venous sinus thrombosis after vaccination with the adenoviral vector ChAdOx1 nCoV-19 COVID-19 vaccine. Assessment of the Extended Glasgow Outcome Scale was performed within 3-6 months after the initial hospital admissions. Patient outcomes ranged from good recovery (13 patients, 29.6%) to moderate disability (11 patients, 25.0%) and severe disability or vegetative state (6 patients, 13.6%). Fatal outcomes were reported in 14 patients (31.8%).

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article